Victory Capital Management Inc. Raises Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Victory Capital Management Inc. grew its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 143.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,745 shares of the company’s stock after buying an additional 17,525 shares during the period. Victory Capital Management Inc.’s holdings in Janux Therapeutics were worth $1,351,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC grew its position in Janux Therapeutics by 1.8% in the first quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock worth $73,961,000 after acquiring an additional 34,069 shares during the period. Vanguard Group Inc. lifted its stake in shares of Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares during the last quarter. Logos Global Management LP grew its holdings in shares of Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after purchasing an additional 600,000 shares during the period. Samlyn Capital LLC increased its position in shares of Janux Therapeutics by 9.6% during the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock worth $13,602,000 after purchasing an additional 28,312 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth about $5,715,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 3.0 %

Shares of NASDAQ JANX opened at $48.82 on Tuesday. The stock has a market cap of $2.56 billion, a P/E ratio of -41.73 and a beta of 3.52. The business’s fifty day simple moving average is $50.05 and its 200-day simple moving average is $45.83. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. The firm’s quarterly revenue was down 82.6% on a year-over-year basis. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.

Analyst Ratings Changes

JANX has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. Leerink Partners assumed coverage on Janux Therapeutics in a research report on Friday. They issued an “outperform” rating and a $79.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research note on Thursday, November 7th. Finally, Scotiabank cut their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $67.70.

Insider Activity at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $42.33, for a total value of $92,364.06. Following the transaction, the insider now owns 7,000 shares of the company’s stock, valued at $296,310. This represents a 23.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the completion of the sale, the chief executive officer now owns 307,054 shares in the company, valued at approximately $14,219,670.74. This represents a 7.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 420,610 shares of company stock valued at $19,288,666 over the last 90 days. 29.40% of the stock is owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.